Literature DB >> 26780004

Non-high-density lipoprotein cholesterol: current status as cardiovascular marker.

Rutger Verbeek1, G Kees Hovingh, S Matthijs Boekholdt.   

Abstract

PURPOSE OF REVIEW: In this review, we summarize the evidence with regard to the rationale of using nonhigh density lipoprotein cholesterol (non-HDL-C) as a cardiovascular disease (CVD) risk factor, in relation to low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB). RECENT
FINDINGS: In the 2015 National Lipid Association Annual Summary non-HDL-C is considered a coprimary target, apart from LDL-C. The other data published in the last 18 months about non-HDL-C support all the previous published data. There are no recent findings, which we deem to cause a change of the current opinion about non-HDL-C as a predictor for CVD.
SUMMARY: The existing evidence supports the claim that non-HDL-C is superior to LDL-C in CVD risk estimation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26780004     DOI: 10.1097/MOL.0000000000000237

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  18 in total

Review 1.  Integrating Advanced Lipid Testing and Biomarkers in Assessment and Treatment.

Authors:  Alexandra Vaio Sykes; Neeja Patel; Danielle Lee; Pam R Taub
Journal:  Curr Cardiol Rep       Date:  2022-08-24       Impact factor: 3.955

2.  Non-HDL-c/TC: A Novel Lipid-Related Marker in the Assessment of Severity of Coronary Artery Lesions and Cardiovascular Outcomes.

Authors:  Anan Huang; Xin Qi; Liping Wei; Mingyin Zhang; Shiqi Zhou
Journal:  Cardiol Res Pract       Date:  2019-04-23       Impact factor: 1.866

3.  Non-High-Density Lipoprotein Cholesterol Levels on the Risk of Asymptomatic Intracranial Arterial Stenosis: A Result from the APAC Study.

Authors:  Jianwei Wu; Anxin Wang; Xin Li; Shouling Wu; Xingquan Zhao
Journal:  Sci Rep       Date:  2016-11-18       Impact factor: 4.379

4.  Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.

Authors:  Dirk Müller-Wieland; Lawrence A Leiter; Bertrand Cariou; Alexia Letierce; Helen M Colhoun; Stefano Del Prato; Robert R Henry; Francisco J Tinahones; Lisa Aurand; Jaman Maroni; Kausik K Ray; Maja Bujas-Bobanovic
Journal:  Cardiovasc Diabetol       Date:  2017-05-25       Impact factor: 9.951

5.  Health benefits of late-onset metformin treatment every other week in mice.

Authors:  Irene Alfaras; Sarah J Mitchell; Hector Mora; Darisbeth Rosario Lugo; Alessandra Warren; Ignacio Navas-Enamorado; Vickie Hoffmann; Christopher Hine; James R Mitchell; David G Le Couteur; Victoria C Cogger; Michel Bernier; Rafael de Cabo
Journal:  NPJ Aging Mech Dis       Date:  2017-11-20

6.  Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials.

Authors:  Om P Ganda; Jorge Plutzky; Santosh K Sanganalmath; Maja Bujas-Bobanovic; Andrew Koren; Jonas Mandel; Alexia Letierce; Lawrence A Leiter
Journal:  Diabetes Obes Metab       Date:  2018-07-02       Impact factor: 6.577

7.  There is a U shaped association between non high density lipoprotein cholesterol with overall and cardiovascular mortality in chronic kidney disease stage 3-5.

Authors:  Hsuan Chiu; Pei-Yu Wu; Jiun-Chi Huang; Hung-Pin Tu; Ming-Yen Lin; Szu-Chia Chen; Jer-Ming Chang
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

8.  Inverse Association Between Serum Non-High-Density Lipoprotein Cholesterol Levels and Mortality in Patients Undergoing Incident Hemodialysis.

Authors:  Tae Ik Chang; Elani Streja; Gang Jee Ko; Neda Naderi; Connie M Rhee; Csaba P Kovesdy; Moti L Kashyap; Nosratola D Vaziri; Kamyar Kalantar-Zadeh; Hamid Moradi
Journal:  J Am Heart Assoc       Date:  2018-06-09       Impact factor: 5.501

9.  Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice.

Authors:  Marianne G Pouwer; Elsbet J Pieterman; Nicole Worms; Nanda Keijzer; J Wouter Jukema; Jesper Gromada; Viktoria Gusarova; Hans M G Princen
Journal:  J Lipid Res       Date:  2019-12-16       Impact factor: 5.922

10.  The U-Shaped Association of Non-High-Density Lipoprotein Cholesterol Levels With All-Cause and Cardiovascular Mortality Among Patients With Hypertension.

Authors:  Qi Cheng; Xiao-Cong Liu; Chao-Lei Chen; Yu-Qing Huang; Ying-Qing Feng; Ji-Yan Chen
Journal:  Front Cardiovasc Med       Date:  2021-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.